Publications by authors named "Ronald Black"

Claim this Profile
L
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study.
Stephen P Salloway, Reisa Sperling, Nick C Fox, Marwan N Sabbagh, Lawrence S Honig, Ronald S Black

J Alzheimers Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.
Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan, Ronald S Black

Alzheimers Res Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
Rik Vandenberghe, Juha O Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens, Ronald S Black

Alzheimers Res Ther· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB.
John Harrison, Dorene M Rentz, Trent McLaughlin, Timothy Niecko, Keith M Gregg, Ronald S Black

Clin Neuropsychol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Stephen Salloway, Reisa Sperling, Nick C Fox, Kaj Blennow, William Klunk, Ronald Black

N Engl J Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease.
Kasia Lobello, J Michael Ryan, Enchi Liu, Gregory Rippon, Ronald Black

Int J Alzheimers Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
Kaj Blennow, Henrik Zetterberg, Juha O Rinne, Stephen Salloway, Jenny Wei, Ronald Black

Arch Neurol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
Reisa Sperling, Stephen Salloway, David J Brooks, Donatella Tampieri, Jerome Barakos, Ronald Black

Lancet Neurol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.
Reisa A Sperling, Clifford R Jack, Sandra E Black, Matthew P Frosch, Steven M Greenberg, Ronald S Black

Alzheimers Dement· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global issues in drug development for Alzheimer's disease.
Rachelle S Doody, Patricia E Cole, David S Miller, Eric Siemers, Ronald Black

Alzheimers Dement· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single ascending dose study of bapineuzumab in patients with Alzheimer disease.
Ronald S Black, Reisa A Sperling, Beth Safirstein, Ruth N Motter, Allan Pallay

Alzheimer Dis Assoc Disord· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.
Juha O Rinne, David J Brooks, Martin N Rossor, Nick C Fox, Roger Bullock, Ronald Black

Lancet Neurol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scales as outcome measures for Alzheimer's disease.
Ronald Black, Barry Greenberg, J Michael Ryan, Holly Posner, Jeffrey Seeburger

Alzheimers Dement· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
Michael Pride, Peter Seubert, Michael Grundman, Michael Hagen, John Eldridge, Ronald S Black

Neurodegener Dis· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.
Basil H Ridha, Valerie M Anderson, Josephine Barnes, Richard G Boyes, Shona L Price, Ronald S Black

J Neurol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A neuropsychological test battery for use in Alzheimer disease clinical trials.
John Harrison, Sonia L Minassian, Lisa Jenkins, Ronald S Black, Martin Koller

Arch Neurol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.
Stéphanie Bombois, Claude-Alain Maurage, Marie Gompel, Vincent Deramecourt, Marie-Anne Mackowiak-Cordoliani, Ronald S Black

Arch Neurol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells.
Margot O'Toole, Derek B Janszen, Donna K Slonim, Padmalatha S Reddy, Debra K Ellis, Ronald S Black

Arch Neurol· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Michael Lee, Frederique Bard, Kelly Johnson-Wood, Celeste Lee, Kang Hu, Ronald S Black

Ann Neurol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Over-the-counter medications in pregnancy.
Ronald A Black, D Ashley Hill

Am Fam Physician· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis